KR102053674B1 - 비-천연 컨센서스 알부민 결합 도메인 - Google Patents

비-천연 컨센서스 알부민 결합 도메인 Download PDF

Info

Publication number
KR102053674B1
KR102053674B1 KR1020147035989A KR20147035989A KR102053674B1 KR 102053674 B1 KR102053674 B1 KR 102053674B1 KR 1020147035989 A KR1020147035989 A KR 1020147035989A KR 20147035989 A KR20147035989 A KR 20147035989A KR 102053674 B1 KR102053674 B1 KR 102053674B1
Authority
KR
South Korea
Prior art keywords
ala
lys
glu
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147035989A
Other languages
English (en)
Korean (ko)
Other versions
KR20150016585A (ko
Inventor
스티븐 제이콥스
Original Assignee
얀센 바이오테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 바이오테크 인코포레이티드 filed Critical 얀센 바이오테크 인코포레이티드
Publication of KR20150016585A publication Critical patent/KR20150016585A/ko
Application granted granted Critical
Publication of KR102053674B1 publication Critical patent/KR102053674B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020147035989A 2012-05-25 2013-05-23 비-천연 컨센서스 알부민 결합 도메인 Active KR102053674B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651642P 2012-05-25 2012-05-25
US61/651,642 2012-05-25
US201361776918P 2013-03-12 2013-03-12
US61/776,918 2013-03-12
PCT/US2013/042429 WO2013177398A2 (en) 2012-05-25 2013-05-23 Non-natural consensus albumin binding domains

Publications (2)

Publication Number Publication Date
KR20150016585A KR20150016585A (ko) 2015-02-12
KR102053674B1 true KR102053674B1 (ko) 2019-12-09

Family

ID=49622071

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147035989A Active KR102053674B1 (ko) 2012-05-25 2013-05-23 비-천연 컨센서스 알부민 결합 도메인

Country Status (15)

Country Link
US (3) US9156887B2 (https=)
EP (1) EP2855509B1 (https=)
JP (3) JP2015519345A (https=)
KR (1) KR102053674B1 (https=)
CN (1) CN104470944B (https=)
AU (2) AU2013266215B2 (https=)
BR (1) BR112014029409B1 (https=)
CA (1) CA2874646C (https=)
DK (1) DK2855509T3 (https=)
EA (1) EA036487B1 (https=)
ES (1) ES2670442T3 (https=)
IL (2) IL235808A (https=)
MX (1) MX355041B (https=)
PT (1) PT2855509T (https=)
WO (1) WO2013177398A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
WO2014140882A2 (en) * 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
JP2018518945A (ja) * 2015-04-29 2018-07-19 メディオラヌム・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ 可溶性キメラインターロイキン−１０受容体およびその療法使用
US10456442B2 (en) * 2015-06-18 2019-10-29 Albert Einstein College Of Medicine FGF receptor ligands for treating diabetes and obesity
EP3374504B1 (en) * 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
CN106699842B (zh) * 2015-11-17 2020-06-12 上海交通大学 一种新的抗炎小分子多肽及其应用
CA3054286A1 (en) 2016-03-01 2017-09-08 The Board Of Trustees Of The University Of Illinois L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
CN110225770B (zh) 2016-12-14 2022-04-26 杨森生物科技公司 结合cd8a的纤连蛋白iii型结构域
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
WO2018140456A1 (en) 2017-01-24 2018-08-02 Northwestern University Active low molecular weight variants of angiotensin converting enzyme 2 (ace2)
JP7744621B2 (ja) 2017-08-11 2025-09-26 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 切断されたモルモットｌ－アスパラギナーゼバリアントおよび使用の方法
JP7545894B2 (ja) 2018-03-13 2024-09-05 アフィボディ アクティエボラーグ 新規足場に基づくポリペプチド
KR102282240B1 (ko) * 2018-12-06 2021-07-28 경상국립대학교산학협력단 지속형 엑센딘-4 및 이의 용도
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CN119119240A (zh) 2019-10-14 2024-12-13 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
CN115175691B (zh) 2019-12-18 2026-02-10 Aro生物疗法公司 结合血清白蛋白的纤连蛋白iii型结构域及其应用
US12123036B2 (en) 2020-02-26 2024-10-22 Northwestern University Soluble ACE2 variants and uses therefor
US20240293487A1 (en) * 2020-03-25 2024-09-05 Jin-Woo Choi Immunoevasive anti-tumor adenovirus
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
EP4323008A4 (en) 2021-04-14 2026-02-25 Aro Biotherapeutics Company FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES
CN113336860B (zh) * 2021-06-02 2022-07-01 北京大学 一种具有靶向和长效功能的重组水蛭素融合蛋白及其编码基因和应用
KR20250087648A (ko) * 2022-11-09 2025-06-16 리플리겐 코포레이션 친화도 제제
EP4634216A1 (en) 2022-12-16 2025-10-22 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
WO2025125378A1 (en) * 2023-12-12 2025-06-19 Navigo Proteins Gmbh Novel serum albumin-binding fusion proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
WO2011137319A2 (en) 2010-04-30 2011-11-03 Centocor Ortho Biotech Inc. Stabilized fibronectin domain compositions, methods and uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
DE69329877T2 (de) * 1992-05-07 2001-04-26 Affitech A/S, Oslo Von L Protein abgeleitete Immunoglobulin-bindende Proteine und deren anwendungen
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
PT1015576E (pt) 1997-09-16 2005-09-30 Egea Biosciences Llc Metodo para a sintese quimica completa e montagem de genes e de genomas
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP2190863B1 (en) 2007-07-31 2015-09-02 Affibody AB New albumin binding compositions, methods and uses
CA2729567C (en) 2008-06-30 2018-04-24 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
ES2705714T3 (es) * 2008-10-31 2019-03-26 Janssen Biotech Inc Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
WO2010092963A1 (ja) * 2009-02-10 2010-08-19 国立大学法人 琉球大学 薬物運搬体並びにこれを利用したアジュバントおよびワクチン
BRPI1008532B1 (pt) 2009-02-12 2021-12-14 Janssen Biotech, Inc Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
EA201690310A1 (ru) 2010-04-13 2016-12-30 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
WO2011137319A2 (en) 2010-04-30 2011-11-03 Centocor Ortho Biotech Inc. Stabilized fibronectin domain compositions, methods and uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Jacobs, S.A. ET AL., PROTEIN ENG DES SEL, vol. 25, pp. 107-117 (2012.01.12.)
JONSSON, A. ET AL., PROTEIN ENG DES SEL, vol. 21, pp. 515-527 (2008.01.01.)

Also Published As

Publication number Publication date
US20130316952A1 (en) 2013-11-28
BR112014029409A2 (https=) 2017-08-15
CA2874646C (en) 2020-12-01
JP2018171063A (ja) 2018-11-08
WO2013177398A2 (en) 2013-11-28
AU2017261625A1 (en) 2017-12-07
IL254652A0 (en) 2017-11-30
CA2874646A1 (en) 2013-11-28
US20160083436A1 (en) 2016-03-24
EA201590136A1 (ru) 2016-02-29
CN104470944A (zh) 2015-03-25
MX355041B (es) 2018-03-28
ES2670442T3 (es) 2018-05-30
IL235808A0 (en) 2015-01-29
HK1209134A1 (en) 2016-03-24
WO2013177398A3 (en) 2014-03-27
EA036487B1 (ru) 2020-11-16
DK2855509T3 (en) 2018-07-23
US9156887B2 (en) 2015-10-13
JP2021019595A (ja) 2021-02-18
AU2013266215B2 (en) 2017-12-07
EP2855509A2 (en) 2015-04-08
EP2855509A4 (en) 2016-01-13
JP2015519345A (ja) 2015-07-09
AU2017261625B2 (en) 2019-11-21
KR20150016585A (ko) 2015-02-12
PT2855509T (pt) 2018-08-03
JP7166081B2 (ja) 2022-11-07
IL254652B (en) 2019-12-31
US10280200B2 (en) 2019-05-07
US20180009854A1 (en) 2018-01-11
MX2014014384A (es) 2015-05-11
BR112014029409B1 (pt) 2022-11-29
EP2855509B1 (en) 2018-05-02
CN104470944B (zh) 2021-09-14
AU2013266215A1 (en) 2014-12-04
IL235808A (en) 2017-10-31

Similar Documents

Publication Publication Date Title
KR102053674B1 (ko) 비-천연 컨센서스 알부민 결합 도메인
CN102781960B (zh) Hsa相关组合物及使用方法
KR102461666B1 (ko) 혈청 알부민 결합 피브로넥틴 iii 형 도메인
CN105477641A (zh) 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途
WO2012088006A1 (en) Fibronectin based scaffold domain proteins that bind il-23
CN106457070A (zh) 基于IL‑15/IL‑15Rα的缀合物的纯化方法
CA2837875A1 (en) Human fusion proteins comprising interferons and targeted modified ubiquitin proteins
WO2013186329A1 (en) Human fusion proteins comprising single chain tnfalpha and targeting domains
US6492492B1 (en) Circularly permuted biotin binding proteins
CN117858982A (zh) 人纤连蛋白iii型蛋白支架
HK1209134B (en) Non-natural consensus albumin binding domains
EA045108B1 (ru) Выделенный искусственный альбумин-связывающий домен и содержащий его слитый белок
US20180118799A1 (en) Cyclized cytokine and method for producing same
HK40006036A (en) Serum albumin-binding fibronectin type iii domains

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7